MAPK3 and frontotemporal dementia: In addition, the combination of regorafenib plus FTD revealed that cell survival is reduced to a higher extent when FTD is administered prior to regorafenib; this can be explained by a greater decrease in phospho-ERK1/2 and thymidylate synthase (TS) expression, which induces cell death62.